Elanco Animal Health Incorporated (ELAN)

Market Cap	8.85B
Revenue (ttm)	4.48B
Net Income (ttm)	434.00M
Shares Out	496.81M
EPS (ttm)	0.88
PE Ratio	20.35
Forward PE	19.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,169,567
Open	17.49
Previous Close	17.43
Day's Range	17.42 - 17.83
52-Week Range	8.02 - 17.83
Beta	1.66
Analysts	Buy
Price Target	17.33 (-2.7%)
Earnings Date	Aug 7, 2025

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,450
• Stock Exchange: NYSE
• Ticker Symbol: ELAN
• Website: https://www.elanco.com

Analyst Forecast

According to 7 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price target is $17.33, which is a decrease of -2.70% from the latest price.

Price Target

$17.33

(-2.70% downside)

Analyst Consensus: Buy